# TABLE OF CONTENTS

## HIGHLIGHTS

623  Selected Articles from This Issue

## MCT FIRST DISCLOSURES

625  F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd

Joel Morris, Donn G. Wishka, Omar D. Lopez, Vladimir Rudchenko, Guangfei Huang, Sierra N. Hoffman, Suzanne Borgel, Kyle Georgius, Jerry M. Collins, Melinda G. Hollingshead, and Beverly A. Teicher

## REVIEW

632  Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in Its Small Molecule Targeting for Cancer Management

Debra R. Garvey, Gagan Chhabra, Mary A. Ndiaye, and Nihal Ahmad

## SMALL MOLECULE THERAPEUTICS

641  ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aime R. Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jiyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S. Chambers, Cloud P. Paveletz, Shripad V. Bhagwat, Jason R. Manro, Ramon V. Tiu, and Pasie A. Jänne

655  Molecular Targeting of RRM2, NFκB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer

Elizabeth A. Wilson, Nahid Sultan, Khyati N. Shah, Howard L. Elford, and Jesika S. Faridi

665  ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaasmin Shiny Jecaraj, Jade A. Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E. Allen, Steven I. Sherman, Michelle D. Williams, and Robert F. Gagel

676  PI3K-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

Mario Scarpa, Prerna Singh, Christopher M. Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus, Sandrine Niyongere, Jaya Sangodkar, Yin Wang, Danilo Perrotti, Goutham Narla, and Maria R. Baer

691  Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Shogo Shigeta, Goldie Y.L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori, and Christopher J. Kemp

## LARGE MOLECULE THERAPEUTICS

716  Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer

Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulou, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hitzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Odaci, Daniel Bravo-Perez, Elaine Mai, Dionysis Slaga, Diego Ellerman, James Ziai, Klara Totpal, Gene Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, and Teemu T. Junttila
### TABLE OF CONTENTS

#### CANCER BIOLOGY AND TRANSLATIONAL STUDIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>739</td>
<td>V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer</td>
<td>Bradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, Graham Packham, and Simon J. Crabb</td>
</tr>
</tbody>
</table>

#### MODELS AND TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**ABOUT THE COVER**

In this issue of *Molecular Cancer Therapeutics*, Morris and colleagues disclose a novel fluorine-containing cytidine analog, F-aza-T-dCyd. F-aza-T-dCyd produced complete regressions in the HL-60 model pictured, as well as in xenografts of bladder and colon cancer. Their disclosure supports the continued development of F-aza-T-dCyd as a new therapeutic in a category that has seen five FDA approvals. Read the full manuscript on page 625.
Molecular Cancer Therapeutics

20 (4)

Mol Cancer Ther 2021;20:623-760.

Updated version  Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/4

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/20/4. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.